AI-powered drug discovery and biodefence company Lunai Bioworks (NASDAQ:LNAI) announced on Tuesday that it has received its first Letter of Intent (LOI) to license its next-generation immune cell therapy, which achieved complete regression of both primary and metastatic pancreatic tumours with no recurrence in humanised preclinical models.

This follows Lunai's recent peer-reviewed publication in Vaccines, a successful pre-IND meeting with the US Food and Drug Administration (FDA), and growing third-party recognition from the biotechnology and scientific communities, the company said.

Lunai has proposed a Phase I clinical trial assessing its Dendritic Cell Combination Therapy (DCCT) across several high-need solid tumours, including pancreatic cancer, which currently has a five-year survival rate of just 13%.

David Weinstein, Lunai Bioworks CEO, said: "We are seeing accelerating validation from both researchers and industry partners. Independent expert analysis confirms the strength of our data, while early licensing activity reflects growing confidence in this platform's potential to unlock scalable, off-the-shelf treatments capable of reaching the patients who need them most."